Is There NO Treatment For Severe Sepsis?

نویسندگان

  • AS Bredan
  • A Cauwels
چکیده

Sepsis is a systemic inflammatory response syndrome in the presence of suspected or proven infection, and it may progress to or encompass organ failure (severe sepsis) and hypotension (septic shock). Clinicians possess an arsenal of supportive measures to combat severe sepsis and septic shock, and some success, albeit controversial, has been achieved by using low doses of corticosteroids or recombinant human activated protein C. However, a truly effective mediator-directed specific treatment has not been developed yet. Treatment with low doses of corticosteroids or with recombinant human activated protein C remains controversial and its success very limited. Attempts to treat shock by blocking LPS, TNF or IL-1 were unsuccessful, as were attempts to use interferon-gamma or granulocyte colony stimulating factor. Inhibiting nitric oxide synthases held promise but met with considerable difficulties. Scavenging excess nitric oxide or targeting molecules downstream of inducible nitric oxide synthase, such as soluble guanylate cyclase or potassium channels, might offer other alternatives.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

بررسی سیتوکینهایTh1-Th2 در سطح سلولی در بیماران مبتلا به سپسیس و سپسیس شدید

Background: Sepsis is the leading cause of death in critically ill patients throughout the world. The incidence is increasing despite the major advances in the development of antimicrobial agents and other supportive treatments. Based on multiple studies, it has been shown that patient outcome depends on Th1 and Th2 cytokine response. Moreover, whenever the Th2 response is predominant, the seps...

متن کامل

Use of honey as a treatment for severe echtyma gangrenosum

For more than 25 years, honey has been employed to facilitate the healing of complex wounds with excellent results. Here, we report the case of a two-and-a-half-year-old agammaglobulinemia patient admitted in our unit for severe sepsis with extensive skin necrosis in the groin, penis and scrotum. An Ecthyma Gangrenosum was corroborated by the isolation of Pseudomonas aeruginosa in wound s...

متن کامل

The Prognostic Role of Mean Platelet Volume (MPV) in Sever Sepsis: is it True?

Background: The purpose of the present study was to examine the role of mean platelet volume (MPV) in comparison with Sequential Organ Failure Assessment (SOFA), quick SOFA (qSOFA), and Mortality in Severe Sepsis in the Emergency Department (MISSED) scoring systems in predicting hospital mortality among patients with severe sepsis. Methods: This follow-up stud...

متن کامل

Use of Serial C-reactive Protein Measure-ments for Determination of the Length of Empiric Antibiotic Therapy in Suspected Neonatal Sepsis

Background: The management of neonatal sepsis especially in developing countries is problematic.  There is no single reliable marker of infection available at the present.  C-reactive protein (CRP) has long been used as a marker of infection. Serial measurements of CRP are recommended as a guide for duration of antibiotic therapy. Objective: To evaluate the serial CRP measurement as a guideline...

متن کامل

Effect of SeptimebTM as a new natural extract on severe sepsis: A randomized clinical trial

Background: Septimeb as a herbal medicine has regulatory effects on inflammation. This study set to evaluate the effects of Septimeb among patients with sepsis on inflammatory biomarkers and survival rate. Methods: In this randomized clinical trial, 51 patients with sepsis from the ICU and medical ward of Imam Khomeini Hospital were divided into two groups: Septimeb (n=25) and control group ...

متن کامل

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?

Two international multicentre randomised controlled trials of drotrecogin alfa (activated) (DrotAA), the Recombinant Human Activated Protein C Worldwide Evaluation of Severe Sepsis (PROWESS) and Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) trials, have produced inconsistent results. When 28-day mortality data from these trials for patients with severe se...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 3  شماره 

صفحات  -

تاریخ انتشار 2008